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Neovascular age-related macular degeneration is a leading cause of irreversible vision loss in the Western 
world. Cytokine-targeted therapies (such as anti-vascular endothelial growth factor) are effective in treating 
pathologic ocular angiogenesis, but have not led to a durable effect and often require indefinite treatment. 
Here, we show that Nutlin-3, a small molecule antagonist of the E3 ubiquitin protein ligase MDM2, inhibited 
angiogenesis in several model systems. We found that a functional p53 pathway was essential for Nutlin-3–
mediated retinal antiangiogenesis and disruption of the p53 transcriptional network abolished the antian-
giogenic activity of Nutlin-3. Nutlin-3 did not inhibit established, mature blood vessels in the adult mouse 
retina, suggesting that only proliferating retinal vessels are sensitive to Nutlin-3. Furthermore, Nutlin-3 inhib-
ited angiogenesis in nonretinal models such as the hind limb ischemia model. Our work demonstrates that 
Nutlin-3 functions through an antiproliferative pathway with conceivable advantages over existing cytokine-
targeted antiangiogenesis therapies.
Introduction
Neovascular age-related macular degeneration (NV-ARMD) leads 
to irreversible vision loss as a consequence of pathologic angio-
genesis. Intravitreal use of neutralizing antibodies to VEGF-A pro-
vides significant visual rehabilitation (1), but recalcitrant cases are 
emerging, with one study reporting 45% of NV-ARMD patients 
not having the desired response to anti-VEGF monotherapy (2). 
Also, the need for frequent, repeat treatments have clinicians and 
scientists searching for durable treatments that can reduce depen-
dence on anti-VEGF.
Epimacular and extraocular brachytherapy are cytokine-inde-
pendent therapies that are currently being evaluated in clinical 
trial for NV-ARMD (3–5). Ionizing radiation induces free radicals 
and DNA damage to the cellular genome, ultimately leading to 
mobilization of the tumor suppression transcription factor p53 
(6). The short-term side effect profile appears to be favorable in 
these clinical trials, but long-term toxicity concerns remain.
Small-molecule MDM2 inhibitors, such as Nutlin-3, have 
recently been reported and are classically known to disrupt 
MDM2-p53 interaction leading to p53 activation (7). In vitro and 
Matrigel plug endothelial cell studies suggest that Nutlin-3 may 
inhibit angiogenesis (8), but it remains unclear whether Nutlin-3 
possesses antiangiogenesis activity that is biologically relevant. 
Recently, 2 alternative mechanisms that may explain the anti-
angiogenic activity of Nutlin-3 have been proposed: (a) MDM2 
binds to HIF-1α in the p53 binding domain, rendering HIF-1α 
inactive; (b) stimulation of factor inhibiting HIF (9–13). Both 
mechanisms ultimately lead to diminished VEGF transcription 
and are plausible explanations of MDM2-mediated antiangio-
genesis. We aimed to determine whether Nutlin-3 has an antian-
giogenesis in vivo effect and identify the essential mechanisms 
involved in Nutlin-3 antiangiogenesis.
Results
To determine whether Nutlin-3 inhibits angiogenesis, we first 
tested to determine whether Nutlin-3 inhibits proliferation of 
2 blood vessel components: endothelial and SMC proliferation. 
Nutlin-3 is available in racemic form and purified enantiomers 
Nutlin-3A (active form) and Nutlin-3B (150× less potent than 
Nutlin-3A). Nutlin-3 inhibited human and rat retinal microvas-
cular endothelial cell (HRMEC and RRMEC), human umbilical 
vein endothelial cell (HUVEC), and human umbilical vein SMC 
(HUVSMC) proliferation (Figures 1 and 2, and Supplemental 
Figures 1 and 2; supplemental material available online with this 
article; doi:10.1172/JCI67315DS1). HUVECs and HUVSMCs both 
demonstrated time- and dose-dependent inhibition of cell prolif-
eration, while HUVSMCs were sensitive at higher doses of Nut-
lin-3 compared with HUVECs (Figures 1 and 2).
Next, we aimed to identify the mechanism that mediates Nut-
lin-3 HUVEC and HUVSMC inhibition. Immunofluorescence 
and Western blot studies confirmed Nutlin-3A induces p53 and 
downstream target p21 in HUVECs and HUVSMCs (Figure 3). We 
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predicted activation of p53 and subsequent downstream targets 
may inhibit cell proliferation by initiating the apoptosis pathway. 
After 24 hours of incubation with Nutlin-3, flow cytometry dem-
onstrated significantly more double-positive annexin V and prop-
idium iodide HUVECs compared with control cells (Figure 4A). 
Quantitative RT-PCR (qRT-PCR) demonstrated a relative increase 
in the ratio of BAX to BCL-2 (Figure 4D), and increased TUNEL-
positive cells in Nutlin-3–treated HUVECs in serum-depleted 
medium with growth factor supplementation undergo apoptosis, 
contrary to a previous report that Nutlin-3 alone is insufficient to 
mediate HUVEC apoptosis (Figure 4, B and C, and ref. 8). Similar 
experiments demonstrate that Nutlin-3 does not cause HUVEC 
apoptosis in growth medium (Supplemental Figure 3), but does 
cause HRMEC apoptosis in growth medium (Supplemental Fig-
ure 1, B and C). Surprisingly, HUVSMCs treated for 36 hours with 
Nutlin-3 did not undergo apoptosis despite upregulation of p53 
within 8 hours (Figure 3D and Figure 4, E and F).
To determine the necessity of the p53 pathway for the observed 
Nutlin-3–mediated cellular effects, we infected HUVECs with ret-
rovirus expressing either control shRNA or p53 shRNA. Cell viabil-
ity assay demonstrated that p53 shRNA–infected cells had become 
resistant to Nutlin-3A inhibition (Figure 5). Similar cell viability 
experiments using RRMECs and 2 different siRNA p53 sequenc-
es revealed minimal Nutlin-3 activity (Supplemental Figure 2). 
These data suggest that the p53 pathway is critical for Nutlin-3– 
mediated inhibition of endothelial cells.
To test the hypothesis that Nutlin-3–mediated cell death inhibits 
angiogenesis, we performed a capillary tube formation assay that 
measures the ability to form tube-like structures. Our experiments 
revealed a 93% reduction in capillary tube formation in Nutlin-3A– 
treated HUVECs compared with control. Also, the effects of 
Nutlin-3A on inhibiting capillary tube formation appeared to be 
dose dependent (Figure 6).
Next, we used a retinal development model to test the possibility 
that Nutlin-3 could be used to inhibit retinal vessel proliferation 
(Figure 7) (14). We found that subcutaneous Nutlin-3 injection 
in the nape revealed a modest (27.4%), but statistically signifi-
cant, reduction (P < 0.05) in the amount of retinal vessels com-
pared with those in sham-injected mice (Figure 7, B and C). In an 
attempt to reduce systemic toxicity and improve delivery to the 
eye, we performed similar experiments and injected Nutlin-3 in the 
periorbital area under the fused eyelid (15). In these experiments, 
we found 43.8% fewer blood vessels compared with those in the 
sham-injected mice (P < 0.01) (Figure 7, D and E). Although a rare 
Figure 1
Nutlin-3 inhibits HUVEC proliferation. (A) 
Nutlin-3A or Nutlin-3B in 1, 5, or 10 μM 
concentrations was added to proliferat-
ing HUVECs for 36 hours. HUVECs were 
either unchallenged or challenged with 
VEGF-A or FGF-2 during the incubation. 
(B) Cell viability was measured at 12, 
24, and 36 hours after incubation. (C) 
Phase contrast images of representative 
conditions of serum free, unchallenged 
HUVECs at 36 hours. Original magnifi-
cation, ×100.
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event, we were able to detect TUNEL-positive cells that colocalized 
to the retinal endothelium (Griffonia simplicifolia–isolectin B4 [GS-
IB4] lectin stained) in a Nutlin-3–treated eye (Figure 7F).
We entertained the possibility that Nutlin-3 may work through 
noncanonical pathways in vivo. Laser-induced choroidal neovas-
cularization (CNV) is an established model of pathologic ocular 
angiogenesis (16). Hif-1α and VEGF protein expression are sig-
nificantly increased in CNV lesions, and it is conceivable that Nut-
lin-3–mediated antiangiogenesis also occurs through Hif-1α (17). 
We performed a single intravitreal injection of racemic Nutlin-3 or 
DMSO immediately after laser injury and demonstrated that, after 
7 days, Nutlin-3 inhibits pathologic retinal angiogenesis in a dose-
dependent fashion, with peak effect at 10 ng/μl (17.2 μM) (Fig-
ure 8, A and B). To decipher the critical pathway responsible for 
Nutlin-3–mediated antiangiogenesis, we performed similar laser–
induced CNV experiments in p53–/– mice and conditionally inacti-
vated HIF-1α and VEGF-A mice. We observed no statistically sig-
nificant difference in Nutlin-3–treated mice in p53–/–, Hif1aflox/flox, 
and Vegfaflox/flox mice compared with controls (Figure 8, C and D, 
and Supplemental Figure 4).
Thus far, we examined the effect of Nutlin-3A on proliferating 
cells in vitro and in vivo. To determine whether Nutlin-3 has an 
effect on established, nonproliferating blood vessels, we injected 
Nutlin-3 in the vitreous cavity of adult mice. Our analysis demon-
strated that there was no reduction of the retinal vasculature in the 
Nutlin-3–treated eyes compared with the control (P > 0.05) (Fig-
ure 9). Additionally, we were interested in examining the potential 
side effect of neuronal degeneration caused by Nutlin-3. On H&E 
Figure 2
Nutlin-3 inhibits HUVSMC pro-
liferation. (A) Confocal immuno-
fluorescence images are dis-
played characterizing HUVSMCs. 
The panels indicate that these 
cells are vimentin (left panel) 
and smooth muscle actin (middle 
panel) positive but VE-cadherin 
(right panel) negative. Original 
magnification, ×200. (B) Vehicle, 
Nutlin-3B (Nut-3B) (7.5 μM), or 
Nutlin-3A (7.5 μM) was added to 
proliferating HUVSMCs at various 
time points with FGF-2 or 5% FBS. 
Various concentrations (0, 7.5, 15, 
30 μM) of Nutlin-3A were added 
to cultures of serum-free, unchal-
lenged HUVSMCs for 24 hours 
(lower panel). (C) Representative 
images of serum-free HUVSMCs 
supplemented with FGF-2 after 72 
hours of culture. Original magnifi-
cation, ×100. Data are mean ± SD 
and representative of 4 separate 
experiments performed in at least 
duplicate. NS, P > 0.05.
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staining, we did not observe any gross changes in the thickness of 
the neuronal cell layers of the Nutlin-3–treated eyes (Figure 9B). 
These data suggest that Nutlin-3 does not cause vascular oblitera-
tion of existing retinal vessels or is grossly toxic to the neurosen-
sory retina. It also suggests that, like radiation, MDM2 inhibitors 
preferentially target proliferating cells more than nonproliferating 
mature retinal vessels (3, 18).
To determine whether Nutlin-3 inhibits nonocular angiogenesis, 
we performed experiments using the hind limb ischemia model. 
After femoral artery ligation, three different concentrations of 
Nutlin-3 or vehicle control were administered intramuscularly 
at the time of surgery and 2 days thereafter. At day 7, muscles 
from ischemic and contralateral hind limb were harvested and 
processed to quantify blood and lymphatic vessels with CD31/
LYVE-1 immunohistochemistry. The extent of vascularization 
was reported as ischemic to nonischemic ratio, after normaliza-
tion on myocyte number (Figure 10). The delivery of Nutlin-3 at 
86 μM induced a significant inhibition on new blood vessel forma-
tion (–40.15%, P = 0.0316) without affecting lymphangiogenesis 
(Supplemental Figure 5).
Discussion
Nutlin-3 is well known to inhibit tumor cell proliferation and 
angiogenesis, but the precise mechanism of how Nutlin-3 inhib-
its angiogenesis is unclear. The 2 prevailing hypotheses are that 
Nutlin-3 inhibits angiogenesis by reducing tumor load and sub-
sequently stimulus for angiogenesis and that Nutlin-3 induces 
p53-mediated endothelial cell death. A physiologic nontumor 
angiogenesis model is required to decipher the mechanism, so we 
chose retinal angiogenesis models.
We chose a murine retinal vascular development model to inves-
tigate the role of Nutlin-3 as a solitary agent for inhibiting in 
vivo angiogenesis. Normal murine retinal vascular development 
begins in utero and continues after birth (Figure 7A). This model 
is advantageous for the following reasons: (a) the system does 
not rely on a tumor model, so we could study the direct effect of 
MDM2 inhibition on blood vessels, and (b) this in vivo model does 
not require injury or the addition of supraphysiological doses of 
proangiogenic cytokines. Our in vivo data demonstrate that Nut-
lin-3 is capable of inhibiting retinal vascular development. We were 
able to show this using 2 slightly different models of drug deliv-
ery. In our systemic subcutaneous injection experiments, we dem-
onstrated a modest, but statistically significant (P < 0.05), inhi-
bition of the retinal vasculature between Nutlin-3–treated mice 
and sham-injected mice. This difference was accentuated when 
we delivered periocular injections, presumably due to higher con-
centrations of the drug at the local site. Periocular drug delivery 
was chosen because it is an established route of administration 
commonly used in clinical practice (19). In addition, this method 
of drug delivery does not cause retinal trauma, an important fac-
tor for quantitative analysis in neonatal mouse pups with small 
retinas. Also of note, experiments evaluating either route of drug 
delivery were preformed with controls within the same litter. Sev-
eral independent experiments were performed, and the largest lit-
ters were represented. We discovered variations in retinal vascular 
growth between litters of the same aged mice precluding analysis 
Figure 3
Nutlin-3 induces p53 expression and a downstream target in HUVECs and HUVSMCs. (A) HUVECs were seeded on plastic-bottom culture dishes 
precoated with gelatin and treated with either 5 μM of Nutlin-3A, 5 μM of Nutlin-3B, or vehicle after 8 hours. Images were taken with an epifluo-
rescent microscope and are representative of p53 expression (middle column) in the nucleus (left column) of HUVECs. Original magnification, 
×400. (B) Western blot analysis for p53 and p21 was performed on lysates obtained from HUVECs treated with Nutlin-3A, Nutlin-3B, or vehicle in 
various concentrations for 8 hours. (C) Representative magnified confocal images are shown of HUVSMCs treated with either 7.5 μM of Nutlin-3A 
or vehicle after 8 hours. Original magnification, ×200. Nuclear p53 expression is shown in red and TO-PRO-3, a nuclear stain, in blue. (D) Western 
blot analysis for p53 and p21 was performed on lysates obtained from HUVSMCs treated with Nutlin-3A or vehicle.
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Figure 4
Nutlin-3 induces apoptosis in HUVECs but not in HUVSMCs. (A) Representative HUVEC flow cytometry plots from 3 independent experiments 
were run in duplicate for 8 hours. (B) TUNEL staining images of HUVECs. Original magnification, ×200. (C) The ratio of the number of TUNEL-
positive cells to the number of nuclei found in 5 random fields from each condition are counted by 2 masked observers. Data are mean ± SD and 
represent 2 independent experiments. (D) qRT-PCR of HUVECs treated for 4 hours. Relative BAX and BCL-2 expression are presented as a ratio. 
Values are provided as a percentage of DMSO (control) and expressed as mean ± SD. (n = 9 from 3 independent experiments).*P < 0.05. (E) 
Representative HUVEC flow cytometry plots from 3 independent experiments were run in duplicate for 36 hours. (F) qRT-PCR of BAX and BCL-2 
expression in HUVSMCs treated for 4 hours. Values are provided given as a percentage of DMSO (control) ± SD. (n = 12 from 4 independent 
experiments) NS, P > 0.05. Amount of Nutlin-3A and Nutlin-3B was 7.5 μM and that of Etoposide was 10 μM.
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of all the mice as one group. This may be due to differences in 
litter size, where larger litters produced on average smaller pups 
and smaller litters produced relatively larger pups. We hypothesize 
that, like humans, smaller pups have differences in retinal vascular 
maturation compared with larger pups of the same age. Therefore, 
only intralitter analysis was performed.
In addition to Nutlin-3’s effect on endothelial cells, our study 
is the first, to our knowledge, to show it inhibits the in vitro pro-
liferation of SMCs (Figure 2). We discovered that HUVSMCs ini-
tiate a rapid p53 response to Nutlin-3 similar to HUVECs, but 
HUVSMCs may not be as sensitive to p53 upregulation witnessed 
by a delay in cell death. Interestingly, we did not find that Nut-
lin-3–treated HUVSMCs undergo apoptosis as HUVECs do. In our 
mouse retina model, we found that first- and second-order vessels 
can have SMCs around blood vessels, suggested by smooth muscle 
actin whole-mount antibody staining (Supplemental Figure 6). In 
our analysis, we observed that Nutlin-3 preferentially targeted cap-
illaries and smaller blood vessels (data not shown). This suggests 
the possibility that blood vessels ensheathed by SMCs may be pro-
tected from Nutlin-3, although this could not be confirmed with 
in vitro experiments (data not shown).
Laser-induced injury is considered a classic model of CNV (20). 
We demonstrated that Nutlin-3 inhibits CNV in a dose-dependent 
manner and that functional p53 is essential for Nutlin-3–mediated 
antiangiogenesis using p53-knockout mice. Since Nutlin-3 has 
been reported to inhibit HIF-1α expression (9, 11), we condition-
ally inactivated HIF-1α in retinal pigment epithelium (RPE) (AAV1-
VMD2-Cre) using a Cre-loxP system, to evaluate the importance of 
the HIF-1α pathway for Nutlin-3 function. HIF-1α inactivation 
alone substantially reduced CNV volume in the laser injury model as 
expected, but had no further impact on Nutlin-3 antiangiogenesis 
(Figure 8D). To test the downstream target of HIF-1α, similar laser-
induced CNV experiments in Vegfaloxp/loxp were performed and cor-
related with HIF-1α data, demonstrating no further Nutlin-3 anti-
angiogenesis with VEGF-A inactivation (Supplemental Figure 4).
Interplay between the HIF-1α and p53 pathways has been well 
documented, and interestingly, both a synergistic and an antago-
nistic affect have been reported (10). RPE-derived HIF-1α is known 
to be an important factor for laser-induced CNV (21). Oxygen 
availability is a key regulator and determinant of HIF-1α and p53 
expression (10). These interactions deserve further study in the 
laser CNV model, and relative oxygen status, mediated through 
HIF-1α, may lead to differential Nutlin-3 activity.
In summary, we demonstrate that Nutlin-3 substantially reduc-
es retinal angiogenesis. We provide evidence that a functional 
Figure 5
p53 is necessary for Nutlin-3–mediated cell death. (A and B) 
HUVECs were infected with a lentiviral vector expressing p53 or con-
trol shRNA for 48 hours and then underwent puromycin selection for 
72 hours. (A) Cell lysates for Western blot analysis were used to con-
firm knockdown of p53 in shRNA-infected HUVECs. (B) p53 shRNA– 
and control shRNA–infected HUVECs were seeded at 1 × 106 cells in 
6-well plates and incubated with FGF-2 and either Nutlin-3A (7.5 μM) 
or vehicle (DMSO) for 48 hours. Cell proliferation was measured at 48 
hours by manual counting using trypan blue exclusion. Data represent 
mean ± SD. *P < 0.05.
Figure 6
Nutlin-3 inhibits capillary tube formation. (A) HUVECs were seeded 
on Matrigel matrix and incubated with FGF-2 and 7.5 μM of Nutlin-3A, 
5 μM of Nutlin-3A, 7.5 μM of Nutlin-3B, or vehicle (DMSO). The images 
were taken with an inverted light microscope and are representative of 
capillary tube formation at 24 hours. Original magnification, ×100. (B) 
Quantification of Nutlin-3A–mediated capillary tube formation inhibi-
tion. Results are expressed as a ratio of tubule length measured to total 
area examined ± SEM. *P < 0.05.
research article
4176 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 10   October 2013
Figure 7
Nutlin-3 inhibits postnatal retinal vascular proliferation. (A) Postnatal mouse retinal vascular development after birth (upper left panel). The optic 
nerve (ON) at the center of a retinal whole mount with green arrows indicating the direction of postnatal blood vessel growth (upper middle and 
right panels). GS-IB4 lectin staining of a retinal whole mount in the developing mouse pup demonstrating radial growth pattern of postnatal 
development of retinal vasculature. (lower panels). Double asterisks indicate areas of avascular retina. (B and C) Neonatal mice were given 
subcutaneous injections in the nape. (B) The retinal vasculature is abrogated in the Nutlin-3–treated eyes (n = 6) (bottom row) compared with the 
sham-injected mice (n = 4) (middle row). In addition, we noticed loss of smaller caliber vessels (inset, right column) in the Nutlin-3–treated mice. 
(C) The graph represents retinal vasculature measured as a function of pixels compared with the amount of retinal tissue in each mouse eye 
(*P < 0.05, representative of 2 independent experiments). (D and E) Neonatal mice were injected in the periocular area of each eye. (E) Nutlin-3–
treated (lower row) mice (n = 8) have less retinal vasculature compared with sham-injected mice (n = 8) (upper row). (D) Same quantification 
method used in B shows a statistically significant difference between the 2 groups (*P < 0.01, representative of 2 independent experiments). (F) 
Rare TUNEL-positive cells identified in the retinal vasculature of a Nutlin-3–treated mouse. Original magnification, ×400. White arrows point to 
residual fetal vasculature unable to be removed during dissection. Data represent mean ± SD. *P < 0.05. Scale bars: 500 μm.
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MDM2 inhibitors, such as Nutlin-3, offer a new therapeutic strat-
egy for inhibiting retinal angiogenesis and may be complementary 
to existing treatments. Optimization or investigation of other 
MDM2 inhibitors is attractive for the treatment of NV-ARMD.
Methods
Reagents and antibodies. Nutlin-3A and Nutlin-3B were donated by Lubo Vas-
silev (Hoffmann-La Roche Inc.) and used for all experiments except for 
in vivo and RRMEC and HRMEC experiments. Racemic Nutlin-3 (Sigma- 
Aldrich), which contains a 50:50 mixture of Nutlin-3A and Nutlin-3B 
and is approximately half as potent as equal concentrations of Nutlin-3A, 
p53 pathway is critical for Nutlin-3–mediated antiangiogenesis. 
It is conceivable that these effects are restricted to Nutlin-3 and 
that other MDM2 inhibitors work differently. Furthermore, we 
were able to extend our observations to a nonretinal angiogen-
esis model by demonstrating Nutlin-3 antiangiogenesis in a hind 
limb ischemia model.
Epimacular and juxtascleral brachytherapy are being evaluated in 
clinical trials with mixed success (3, 5). MDM2 inhibitors may have 
a more attractive side effect profile, since they do not elicit DNA 
damage and, with repeat administration, may even be more robust 
than a single radiation treatment. Our in vivo results suggest that 
Figure 8
Nutlin-3 inhibits pathologic retinal angiogenesis through the p53 pathway. (A) Stacked confocal image of representative laser-induced CNV 
lesions in racemic Nutlin-3– and DMSO-treated eyes. Racemic Nutlin-3 showed maximal activity at 10 ng/17.2 μM. (B) Quantification of z-stack 
confocal images of laser induced CNV in the respective conditions (n = 16–40). (C) Representative images of littermate controls (upper panels) 
after intravitreal injection of DMSO and racemic Nutlin-3. Similar experiments in p53–/– mice demonstrated no appreciable difference between 
DMSO- and Nutlin-3–injected mice. (n = 10–13). (D) Hif1aflox/flox mice were given either subretinal AAV1-VMD2-Cre or AAV1-VMD2-GFP. HIF-1α 
inhibition had no additional impact on Nutlin-3 antiangiogenesis (n = 6–10). Data represent mean ± SEM. *P < 0.05; **P < 0.0001; NS = P > 0.05. 
P = 0.052 for AAV1-GFP-DMSO vs. AAV1-GFP–Nutlin-3. Scale bars: 100 μm.
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plates after detachment. The cells were allowed to adhere overnight in 
growth medium and then incubated with X-VIVO medium (Cambrex) 
with or without cytokines (10 ng/ml FGF-2 and 2 μg/ml heparin or 
10 ng/ml VEGF-A). For HRMEC experiments, cells were seeded at a con-
centration of 1 × 105 and allowed to settle overnight in 6-cm plates coated 
with attachment factor (Cell Signaling). The next day, fresh 10% FBS and 
EBM medium was added. For HUVEC and HUVSMC cell experiments, an 
equivalent dilution of 100% DMSO, Nutlin-3A, or Nutlin-3B was added at 
concentrations indicated in the results the following day. HRMEC experi-
ments were performed in a similar fashion in serum with racemic Nut-
lin-3 because of the limited availability of Nutlin-3A and Nutlin-3B. Since 
racemic Nutlin-3 contains a 50:50 mixture of Nutlin-3A and Nutlin-3B, a 
higher dose of racemic Nutlin was utilized for these experiments compared 
with those used for HUVECs. After incubation, HUVECs were detached 
with collagenase/EDTA, and HUVSMCs and HRMECs were detached with 
trypsin/EDTA. The cells were manually counted with a Hemacytometer 
(Hausser Scientific) using Trypan blue exclusion.
Matrigel tube assay for in vitro angiogenesis. Matrigel matrix (BD) was kept 
on ice for 24 hours. Then, 200 μl of Matrigel was added to each well of a 
24-well culture plate. After hardening the Matrigel at 37°C for 30 min-
utes, gels were overlaid with 500 μl of X-VIVO medium containing 3 × 104 
HUVECs. Next, endothelial cells were stimulated with 10 ng/ml of FGF-2 
and 2 μg/ml heparin and then incubated with various concentrations of 
DMSO, Nutlin-3A, or Nutlin-3B, in triplicate, as indicated in the results. 
The effect of Nutlin was inspected 24 hours under an inverted light micro-
scope. Nine overlapping images with a ×10 objective were taken of each 
well to perform tubule-length quantification. Adobe Photoshop 7.0 (Adobe 
Systems Inc.) was used to make a montage image of each well. Each mon-
tage image was then imported into LSM Image Browser v3.5 (Carl Zeiss 
Inc.) to measure tubule length. Tubule length was then standardized to the 
overall pixel area examined. A masked observer assessed all measurements.
Western blot analysis. HUVECs and HUVSMCs were incubated at 2 × 106 
in X-VIVO medium and HRMECs in EBM with 10% FBS under various 
conditions, as reported in the results. Western blot extracts were prepared 
by lysing attached cells in cold RIPA buffer in the presence of protease 
inhibitors for HUVECs and HUVSMCs and passive lysis buffer (Promega) 
for HRMECs. After sonication and centrifugation to remove cell debris, 
the protein yield was quantified using the BCA protein assay kit (Pierce 
Biotechnology Inc.). Normalized cell lysates were then mixed with sample 
buffer containing 2-mercaptoethanol and SDS and heated for 5 minutes 
at 95°C. Equal amounts of protein were run on SDS-polyacrylamide gels 
before being transferred to PVDF membranes. Binding of the primary 
antibodies against p53, p21, and β-actin was detected with enhanced che-
miluminescence reagent (Amersham) using HRP-conjugated secondary 
antibody (1:10,000; Amersham).
Immunofluorescence studies. HUVECs were seeded onto collagen-coated 
plastic-bottom culture dishes (MatTek Corp.) that were precoated with 
0.2% gelatin. Nutlin-3A and Nutlin-3B were diluted to a concentration of 
5 μM in X-VIVO medium for 8 hours. Immunofluorescence images with a 
was used for these experiments. For hind limb ischemia experiments, Nut-
lin-3 (Sigma-Aldrich) was dissolved in 4% ethanol, 35% propylene glycol 
(Fisher Scientific), 10% PEG-400 (Sigma-Aldrich), and 51% PBS as previ-
ously reported at 100 μg/ml (172 μM) (22).
Primary antibodies included the following: mouse p53 antibody (1:100 
[Western blot] and 1:50 [Immunofluorescence]; Santa Cruz Biotechnol-
ogy Inc.), mouse p21 antibody (1:100; Oncogene), rat β-actin (1:1,000; 
Sigma-Aldrich), mouse smooth muscle actin clone 1A4 (1:100 [whole 
mount and cells]; Dako), goat VE-Cadherin (1:100; R&D Systems), and 
mouse vimentin (1:25; Dako). Secondary antibodies included the follow-
ing: HRP anti-rabbit (1:10,000; Amersham) and HRP anti-mouse (1:10,000; 
Amersham) for Western blot analysis and Cy2 and Cy3 anti-mouse (Jack-
son Immunoresearch), used for immunofluorescence. TO-PRO-3 (1:1000; 
Molecular Probes/Invitrogen) and DAPI (1:1000; Vector Laboratories) were 
used for nuclear staining. GS-IB4–FITC (1:200; Vector Laboratories) and 
GS-IB4–Alexa Fluor 644 (20 mg/ml; Molecular Probes) were used for stain-
ing the retinal vasculature. Anti-CD31 (BD Biosciences) or anti–LYVE-1 
antibodies (Abcam), followed by biotin-labeled goat anti-rat secondary 
antibodies (Dako), were used to stain blood vessels for hind limb ischemia.
Cell harvest. HUVECs and HUVSMCs (gifts of George Lam and Fan 
Zhang, Cornell University, New York, New York, USA) were isolated from 
the umbilical cord veins with collagenase and were cultured in M199 medi-
um containing 10% (vol/vol) FBS, 20 μg/ml endothelial cell growth factor, 
50 μg/ml heparin, 100 μg/ml penicillin, and 100 μg/ml streptomycin in a 
humidified incubator at 37°C with air/5% CO2. HUVEC and HUVSMC 
monolayers from passages 2–4 were used in these studies. HRMECs (Cell 
Systems) were incubated in culture containing endothelial basal medi-
um (EBM) (Cambrex), 10% FBS, and antibiotic/antimycotic solution 
(Sigma-Aldrich). RRMECs (Cell Biologics Inc.) were cultured following 
the supplier’s instruction.
Cell proliferation assay. Cells were seeded at a concentration of 2 × 105 for 
HUVECs and 2 × 104 for HUVSMCs in serum-free medium on 12-well 
Figure 9
Nutlin-3 does not target preexisting blood vessels. (A and B) Adult mice 
received a single intravitreal injection of Nutlin-3 or DMSO to investigate 
the effects of Nutlin-3 on established blood vessels. (A) Confocal images 
of GS-IB4 lectin–stained and (B) H&E-stained paraffin-embedded sec-
tions of retinal vasculature 5 days after injection. Scale bars: 500 μm 
(A); 100 μm (B).(C) Quantification of retinal vessels shows no difference 
between sham- (n = 8) and Nutlin-3–injected mice (n = 8) Data represent 
mean ± SD. NS, P > 0.05, summation of 2 independent experiments.
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Flow cytometric analysis for apoptosis. HUVECs and HUVSMCs were incubated 
with 7.5 μM of Nutlin-3A or DMSO for 24 hours (HUVECs) and 48 hours 
(HUVSMCs) in X-VIVO medium with FGF-2 (10 ng/ml) and heparin (2 μg/
ml). HUVECs were detached with collagenase/EDTA and HUVSMCs were 
detached with trypsin/EDTA. The cells were then washed twice with PBS 
and stained with propidium iodide and annexin V–FITC (Annexin V-FITC 
Apoptosis Detection Kit I, BD) according to the manufacturer’s instructions.
TUNEL assay for apoptosis. HUVECs were plated on collagen-coated plas-
tic-bottom culture dishes (MatTek Corp.) overnight. HUVECs were then 
treated with varying concentrations of Nutlin-3A and Nutlin-3B in X-VIVO 
medium for 24–72 hours. HRMECs were treated with 15 μM of racemic 
Nutlin for 24 hours in 10% FBS. The TUNEL assay was performed follow-
ing instructions provided with the kit (Roche Applied Science). Represen-
tative images of the HRMEC experiment were provided with a ×4 objective 
using an Olympus AX70 fluorescence microscope following the addition 
of a nuclear counter stain. For HUVEC experiments, 5 representative fields 
with a ×20 objective using a Zeiss confocal microscope were captured. Two 
masked observers performed cell counts. For whole-mount retina stain-
ing, samples were incubated in TUNEL solution diluted in PBS plus 0.3% 
Triton-X 100 for 48 hours after lectin staining.
siRNA and shRNA p53 for HUVECs and RRMECs. Passage 3 HUVECs were 
grown to confluence. shRNA pRETRO-SUPER and pRETRO-SUPER-
p53 viruses (gift from Reuven Agami, The Netherlands Cancer Institute, 
Amsterdam, the Netherlands) were produced by GP2 cells (Clontech) (23). 
Supernatant was filtered and then added to HUVECs in the presence of 
4 mg/ml polybrene followed by 1 μg/ml of Puromycin selection for 7 days. 
For the RRMEC cell viability assay, RRMECs were seeded at 3000 cells/
well in a 96-well plate and allowed to adhere overnight in DMEM sup-
plemented with 10% FBS. The next day, cells were transfected with con-
trol siRNA or 2 different siRNA sequences targeting p53 (siRNA p53#1 
5′-AGGAUUCACAGUCGGAUdTdT-3′ and siRNA p53#2 5′-CGACAGG-
GUCACCUAAUdTdT-3′) following lipofectamine protocol (Invitrogen). 
Twenty-four hours after siRNA transfection, the cells were incubated with 
7.5 μM racemic Nutlin-3 or vehicle (DMSO). Cell viability was assessed 
after 36 hours using CellTiter96 AQueous One Solution Cell Proliferation 
Assay Kit (Promega) following the manufacturer’s instruction.
qRT-PCR for Bax-BCL2. qRT-PCR was performed using an ABI 7500 
Fast System (Applied Biosystems) in standard mode. The software used 
to analyze the data was SDS v. 1.3.1 (Applied Biosystems). qRT-PCR was 
performed according to ABI standard protocols. The following primer/
probe sets were obtained through Applied Biosystems (sense and anti-
sense): β-actin (5′-TGACCCAGATCATGTTTGAGA-3′ and 5′-AGTCCAT-
CACGATGCCAGT-3′), BAX (5′-AGCTGCAGAGGATGATTGC-3′ and 
5′-AGTTGAAGTTGCCGTCAGAA-3′), and BCL-2 (5′-AGTACCTGAACC-
GGCACCT-3′ and 5′-CAGCCAGGAGAAATCAAACA-3′). The ΔCt method 
was used to obtain relative quantification, i.e., Ct values of the target gene 
direct light microscope and fluorescent light were captured using a 3CCD 
camera and Qcapture imaging software (Qcapture v 2.81; Quantitative 
Imaging Corp.) or a Carl Zeiss LSM 510 confocal microscope (Carl Zeiss 
Inc.). For hind limb ischemia, 5 nonserial sections were analyzed for each 
hind limb. Images were recorded with a digital camera Leica DC480. Den-
sitometric analysis for CD31 and LYVE-1 staining was performed with 
QwinPro software (Leica). CD31- and LYVE-1–positive areas were normal-
ized to myocyte number and, since CD31 is a panendothelial marker, the 
blood vessel area was calculated subtracting the LYVE-1–positive area from 
the CD31-positive area. Ischemic/nonischemic ratio of vascularized area 
was calculated for each animal.
Figure 10
Nutlin-3 inhibited hind limb ischemia–induced neovascularization. (A) 
Quantification of blood capillary density by CD31 immunostaining, 
expressed as a ratio of ischemic to nonischemic hind limb normalized 
on myocytes number shows that Nutlin-3 significantly reduced heman-
giogenesis when delivered at 86 μM concentration compared with vehi-
cle treatment. At a higher concentration (172 μM), the inhibition was 
similar but not significant (n = 5). (B) Representative pictures of CD31 
immunostaining of capillaries in nonischemic and ischemic muscles 
of lower limbs revealed a robust neovascular response at 7 days in 
the vehicle-treated ischemic hind limb. Treatment with Nutlin-3 resulted 
in significantly reduced CD31 capillary staining in ischemic hind limb 
muscles. Data represent mean ± SEM. *P < 0.05. Scale bar: 100 μm.
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(2–4 spots per eye) of each animal to induce CNV as described (16). 1 μl of 
racemic Nutlin-3 or 1% DMSO was injected into the vitreous cavity with 
a 33-gauge microsyringe (Ito Corporation) immediately after laser injury. 
CNV volumes were measured by scanning laser confocal microscope (TCS 
SP; Leica) as reported with 0.7% FITC-conjugated GS-IB4 (Vector Labo-
ratories) and quantified using ImageJ Software (NIH) (16). Results are 
expressed as mean ± SEM (n refers to number of laser spots). For subretinal 
injection experiments, 1 μl of AAV1-VMD2-Cre or AAV1-VMD2-GFP was 
injected at 1.0 × 1011 PFU/ml on day 0, with subsequent laser coagulation 
and Nutlin-3 treatment 6 days later. CNV quantification occurred 7 days 
after the laser treatment CNV on day 13.
Quantification of retinal vascular development model. We captured images 
with the same laser power, objective, gain, pinhole, and amplifier offset. 
The resultant images were masked to the analyst assessing the images. 
All analyzed images were captured with a ×5 objective and then exported 
to Adobe Photoshop 7.0 as high-resolution tiff images. Using the Magic 
Wand tool and histogram function, the analyst recorded the number of 
pixels that best represented the retinal vasculature and omitted the resid-
ual hyaloidal (fetal) vasculature that was unable to be removed during 
dissection. Blood vessels assessed to be residual hyaloid were found at a 
different focal plane than retinal blood vessels and were usually connected 
to the optic nerve.
Hind limb ischemia model. Briefly, C57BL/6J mice (n = 5 per group) were 
anesthetized before unilateral proximal femoral artery ligation (25, 26). 
The nonischemic left limb underwent a sham surgery without arterial 
ligation. Immediately following surgery and after 48 hours, Nutlin-3 was 
intramuscularly administered at 3 different concentrations (17.2, 86, and 
172 μM) in a total volume of 30 μl to each hind limb. The same volume 
of vehicle was injected in ischemic hind limb of control group as well as 
in the nonischemic left limb of all mice. Seven days later, both anterior 
and posterior muscles from ischemic and nonischemic hind limbs were 
harvested, divided into 2 parts by a central transversal cut, and processed 
for immunohistochemical analysis to quantify angiogenesis and lymphan-
giogenesis. Sections were prepared starting from the exposed central area 
versus distal and proximal sides of the muscles.
Statistics. Comparison values were expressed as a percentage or fold differ-
ence (means ± SEM). P values of less than 0.05 were considered significant 
and calculated using the Mann-Whitney U test (2-tailed), Student’s t test 
(2-tailed), or 1-way ANOVA in Microsoft Excel (Microsoft Corp.) or Sigma-
Plot Ver 12 (Systat Software Inc.).
Study approval. All experiments were performed in accordance with the 
Weill Medical College of Cornell University and the University of Kentucky 
Institutional Animal Care and Use Committee. Husbandry of mice for 
hind limb ischemia procedures was performed in accordance with Europe-
an Directives no. 86/609 and with Italian D.L. 116. The Institute of Genet-
ics and Biophysics veterinarian approved all the experiments.
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trol gene (β-actin). Relative expression was calculated as follows: relative 
expression = (2–ΔCt) × 10,000. No temperature control (NTC) and minus 
RT controls were run appropriately.
Intravitreal injection for in vivo adult retinal vessel assay. Adult, 3-month-old 
129 and C57BL6/129S mice were anesthetized with Avertin and also given 
a drop of topical proparacaine (1%) for local anesthesia. Using a stereo 
microscope, a glass capillary pipette was used to inject 1 ml of either vehicle 
or racemic Nutlin-3 into the vitreous cavity of both eyes of each animal. 
Mice were then euthanized 5 days after injection.
Preparation of retinal whole mounts. The eyes were then fixed in 4% 
paraformaldehyde overnight and washed 3 times with PBS. After removing 
the cornea and lens, the hyaloidal (primitive) vasculature was removed and 
4 radial incisions were made in the eyecup to flatten the retina/choroid/
sclera complex. The choroid and sclera were removed from the retina and 
cut at the optic nerve. After the retinal whole mount was blocked with 5% 
bovine serum albumin, 5% normal donkey serum, and 0.5% Triton X-100 for 
3 hours or overnight, the whole mount was incubated with a 1:200 dilution 
of GS-IB4 lectin overnight and mounted with Vectashield (Vector Laborato-
ries). For double-staining whole-mount experiments, retinas were incubated 
with primary antibody overnight at 4°C and underwent 6 one-hour washes 
with PBS-T, followed by incubation with secondary antibody overnight at 
4°C, followed by 6 one-hour washes with PBS-T prior to being coverslipped 
with Vectashield. Using a fluorescent biomicroscope (Carl Zeiss Discovery 
V12), hyaloidal vessels, vessels connected to the optic nerve, on the surface 
of the retina, were dissected in a masked manner. A confocal laser (Carl Zeiss 
LSM 510 meta) was used to obtain images of the retinal vasculature.
Subcutaneous and periocular injection for in vivo retinal development assay. A 
technique described by Strömblad et al. was modified to study the effects 
of Nutlin-3 on in vivo vascular development (14). Briefly, racemic Nutlin 
was administered by subcutaneous injection in the nape or in the peri-
ocular area of each eye to WT 129 S1-VIMJ (Jackson Laboratories) mouse 
pups within 12 hours of birth. The mice received a total of 4 (fused eyelids 
experiments) or 5 (subcutaneous neck experiments) injections of either 
racemic Nutlin or 100% DMSO. The first injection of Nutlin was adminis-
tered at a dose of 40 mg/kg, while the rest were given at a dose of 80 mg/kg 
for experiments involving injections in the nape. A dose of 80 mg/kg was 
administered for all injections in the fused eyelid series of experiments. The 
pups were euthanized on P2 (periocular) or P3 (nape of neck); the eyes were 
enucleated after the fused eyelids incised.
AAV production. DNAs for the VMD2-CRE/GFP constructs were synthe-
sized, inserted into a bacterial plasmid backbone with appropriate AAV1 
terminal repeats and a polyadenylation sequence to create AAV1 vector 
plasmid DNAs, then amplified in E. coli. Vector preparations were pro-
duced by our standard plasmid cotransfection method (24). Briefly, 1 cell 
factory containing approximately 109 HEK293 cells was transfected by 
CaPO4 precipitation with a 1:3 molar ratio of AAV vector plasmid DNA 
and AAV helper plasmid pDG DNA. The cells were harvested 60 hours 
later, lysed, and the crude lysate purified for vector particles on iodixa-
nol step gradients. Vector-containing fractions were further purified and 
concentrated by FPLC HiTrap Q Sepharose column chromatography with 
final concentration and buffer exchanged into Alcon BSS with 0.014% 
Tween 20. Vector was then titered for DNase-resistant vector genomes by 
Real-Time PCR relative to a standard vector of known titer. Finally, the 
purity of the vector was validated by silver-stained SDS–PAGE, assayed for 
sterility and lack of endotoxin, and then aliquoted and stored at –80°C.
Laser induced CNV model. WT C57BL/6, p53–/–, Hif1aflox/flox mice were pur-
chased from Jackson Laboratory. Vegfaflox/flox mice were a gift from Napo-
leone Ferrara (Genentech). Laser photocoagulation (532 nm, 180 mW, 100 
ms, 75 μm) (Ocu-Light GL; IRIDEX Corp.) was performed on both eyes 
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